Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;28(11):1514-1515.
doi: 10.1016/j.cmi.2022.06.007. Epub 2022 Jun 17.

Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination: Author's response

Affiliations
Comment

Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination: Author's response

Matías J Pereson et al. Clin Microbiol Infect. 2022 Nov.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Mungmunpuntipantip R., Wiwanitkit V. Re: Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination. Clin Microbiol Infect. 2022;28:1513. doi: 10.1016/j.cmi.2022.06.007. - DOI - PMC - PubMed
    1. Pereson J.M., Amaya L., Neukam K., Baré P., Echegoyen N., Badano M.N., et al. Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination induces a stronger humoral response than homologous Sputnik V in a real-world data analysis. Clin Microbiol Infect. 2022;28:1382–1388. doi: 10.1016/j.cmi.2022.05.009. - DOI - PMC - PubMed
    1. Scheiblauer H., Nübling C.M., Wolf T., Khodamoradi Y., Bellinghausen C., Sonntagbauer M., et al. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design. J Clin Virol. 2022;146 - PMC - PubMed
    1. Laham Gustavo, Martínez Alfredo P., Gimenez Wanda Rojas, Lucas Amaya, Abib Anabel, Echegoyen Natalia, et al. Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients [e-pub ahead of print] MedRxiv. 2022 doi: 10.1101/2022.05.13.22275049. Accessed on May 19th. - DOI - PMC - PubMed
    1. Macchia A., Ferrante D., Bouzas M.B., Angeleri P., Biscayart C., Geffner J., et al. Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: results of two randomized clinical trials. Lancet Reg Health Am. 2022;9 - PMC - PubMed

Substances